Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Chilton

Interventional Cardiology San Antonio, TX Doctor of Osteopathy

NPI 1538276514 CMS profile 69149

903 W Martin St, San Antonio, TX 78207

Open in the dashboard

General payments

$1,291,785

950 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Chilton of San Antonio, TX is reported in the CMS Open Payments database as having received $1,291,785 across 950 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142,636 100
2024 General $145,678 102
2023 General $169,602 152
2022 General $209,676 162
2021 General $248,693 172
2020 General $148,203 111
2019 General $227,296 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Chilton
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Robert Chilton were reported at $142,636. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Robert Chilton Interventional Cardiology median Middle half National median
2019 $227,296 $1,097 $329–$3,048 $163
2020 $148,203 $473 $161–$1,480 $114
2021 $248,693 $677 $233–$1,827 $132
2022 $209,676 $978 $333–$2,724 $149
2023 $169,602 $1,136 $382–$2,986 $160
2024 $145,678 $1,181 $395–$3,326 $164
2025 $142,636 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $378,252 185 payments
  2. Lilly USA, LLC $289,781 172 payments
  3. Merck Sharp & Dohme Corporation $183,108 160 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $170,729 133 payments
  5. AstraZeneca Pharmaceuticals LP $50,624 49 payments
  6. Boehringer Ingelheim South Africa (Pty) Ltd $40,832 10 payments
  7. Boehringer Ingelheim MENA (Scientific Office) FZ-LLC $28,785 3 payments
  8. Boehringer Ingelheim International GmbH $26,654 4 payments
  9. Boehringer Ingelheim (Phil.) Inc. $22,850 7 payments
  10. Sanofi-Aventis U.S. LLC $14,088 3 payments
  11. Other $86,080 224 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $991,330 331 payments
  2. Travel and Lodging $143,921 259 payments
  3. Consulting Fee $134,275 31 payments
  4. Food and Beverage $19,396 315 payments
  5. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $2,500 1 payment
  6. Education $364 13 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $240,206 115 payments
  2. JARDIANCE Diabetes $179,670 109 payments
  3. VERQUVO Cardiovascular $151,590 141 payments
  4. Ozempic $121,420 59 payments
  5. TRULICITY $101,500 59 payments
  6. Wegovy $86,435 39 payments
  7. VERQUVO Cardiovascular $76,056 74 payments
  8. JARDIANCE Diabetes $45,471 36 payments
  9. FARXIGA $28,980 36 payments
  10. RYBELSUS $19,263 9 payments
  11. Other $90,341 236 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$4,480

Medicare's payments for the services billed

Medicare patients

23

Average age 75

Services billed

43

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 70%
Heart failure 57%
Chronic kidney disease 57%
Arthritis 57%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$59,379 — —
Wegovy
$22,273 — —
Repatha
$155 — —
FARXIGA
$124 — —
Korlym
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

950 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record